DE69637383D1 - Cytotoxinkonjugate umfassend dipeptide - Google Patents
Cytotoxinkonjugate umfassend dipeptideInfo
- Publication number
- DE69637383D1 DE69637383D1 DE69637383T DE69637383T DE69637383D1 DE 69637383 D1 DE69637383 D1 DE 69637383D1 DE 69637383 T DE69637383 T DE 69637383T DE 69637383 T DE69637383 T DE 69637383T DE 69637383 D1 DE69637383 D1 DE 69637383D1
- Authority
- DE
- Germany
- Prior art keywords
- dipeptide
- cytotoxin conjugate
- residue
- toxin
- cytotoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11193395 | 1995-05-10 | ||
| JP11193395 | 1995-05-10 | ||
| PCT/JP1996/001241 WO1996035451A1 (fr) | 1995-05-10 | 1996-05-10 | Nouveau complexe de toxines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69637383D1 true DE69637383D1 (de) | 2008-02-07 |
| DE69637383T2 DE69637383T2 (de) | 2008-12-11 |
Family
ID=14573780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69637383T Expired - Lifetime DE69637383T2 (de) | 1995-05-10 | 1996-05-10 | Cytotoxinkonjugate umfassend dipeptide |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6103236A (de) |
| EP (1) | EP0867190B1 (de) |
| JP (1) | JP3871713B2 (de) |
| AT (1) | ATE381948T1 (de) |
| CA (1) | CA2220339C (de) |
| DE (1) | DE69637383T2 (de) |
| ES (1) | ES2299177T3 (de) |
| WO (1) | WO1996035451A1 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7642323B2 (en) | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| MXPA00011312A (es) * | 1998-05-20 | 2003-04-22 | Expression Genetics Inc | Un vehiculo de gen polimerico de poli-l.lisina injertada con polietilenglicol con porcion de enfoque hepatocitos. |
| ATE443714T1 (de) * | 1999-05-17 | 2009-10-15 | Conjuchem Biotechnologies Inc | Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen |
| US6258133B1 (en) * | 1999-06-02 | 2001-07-10 | Chevron Chemical Company Llc | Poly (oxyalkylene) pyridyl and piperidyl ethers and fuel compositions containing the same |
| US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
| US7090851B1 (en) | 1999-09-10 | 2006-08-15 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
| DE60038252T2 (de) | 1999-09-30 | 2009-03-19 | Kyowa Hakko Kogyo Co., Ltd. | Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3 |
| CN1284603C (zh) * | 1999-10-08 | 2006-11-15 | 内科塔治疗亚拉巴马公司 | 杂双官能聚乙二醇衍生物和它们的制备方法 |
| KR100502876B1 (ko) * | 2000-04-28 | 2005-07-21 | 아사히 가세이 파마 가부시키가이샤 | 신규 이환성 화합물 |
| WO2002080987A1 (en) * | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
| DE60216151T2 (de) * | 2001-05-31 | 2007-09-27 | ConjuChem Biotechnologies Inc., Montreal | Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion |
| US7129261B2 (en) | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| US20080039532A1 (en) * | 2004-05-06 | 2008-02-14 | Dominique Bridon | Compounds For Specific Viral Target |
| EP1747021B1 (de) * | 2004-05-19 | 2015-09-09 | E. R. Squibb & Sons, L.L.C. | Selbstimmolative verbinder und arzneimittelkonjugate |
| UA85716C2 (en) * | 2004-05-19 | 2009-02-25 | Медарекс, Инк. | Chemical linkers and their conjugates |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| DK1988167T3 (da) * | 2005-02-17 | 2020-07-13 | Univ Sorbonne | Intracellulære inhiberende peptider |
| US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| CN101312748A (zh) * | 2005-09-26 | 2008-11-26 | 梅达莱克斯公司 | 抗体-药物轭合物和使用方法 |
| ES2375843T3 (es) | 2005-10-26 | 2012-03-06 | Medarex, Inc. | Procedimientos y compuestos para la preparación de an�?logos de cc-1065. |
| WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| EP2319542B1 (de) | 2006-02-21 | 2018-03-21 | Nektar Therapeutics | Segmentierte abbaubare Polymere und daraus hergestellte Konjugate |
| US20110182904A1 (en) | 2006-09-05 | 2011-07-28 | Deborah Zimmerman | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| US20090088378A1 (en) * | 2007-01-12 | 2009-04-02 | Omar Quraishi | Long lasting inhibitors of viral infection |
| WO2008103693A2 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
| BRPI0811864A2 (pt) * | 2007-05-16 | 2014-11-18 | Conjuchem Biotechnologies Inc | Derivados de ácido cistéico de peptídeos antivirais |
| EP2214716B1 (de) | 2007-10-23 | 2021-11-17 | Nektar Therapeutics | Auf hydroxyapatite gezielrichtete multiarm polymere und daraus hergestellte konjugate |
| US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| WO2011118739A1 (ja) | 2010-03-26 | 2011-09-29 | 協和発酵キリン株式会社 | 新規修飾部位導入抗体および抗体フラグメント |
| RU2606016C2 (ru) | 2011-01-14 | 2017-01-10 | Редвуд Байосайнс, Инк. | Меченые альдегидом полипептиды иммуноглобулина и способы их применения |
| US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| MY174813A (en) | 2013-03-15 | 2020-05-16 | Zymeworks Inc | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| CA2935077C (en) | 2013-12-27 | 2022-03-15 | Geoffrey C. Winters | Sulfonamide-containing linkage systems for drug conjugates |
| US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
| DK3194421T3 (da) | 2014-09-17 | 2022-02-14 | Zymeworks Inc | Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf |
| CN113350518A (zh) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| CA3019398A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| NZ752394A (en) | 2016-11-14 | 2021-07-30 | Hangzhou Dac Biotech Co Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| EP4141017A1 (de) | 2020-04-24 | 2023-03-01 | The University of Tokyo | Duocarmycinderivat und verwendung davon |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) * | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
| JPS6067433A (ja) | 1983-09-24 | 1985-04-17 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン類，多糖類及び抗体の複合体 |
| US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| JPS6335575A (ja) | 1986-07-31 | 1988-02-16 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン誘導体 |
| JPS63246336A (ja) | 1986-11-10 | 1988-10-13 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン−抗体複合体含有組成物 |
| JPS63150282A (ja) * | 1986-12-13 | 1988-06-22 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン誘導体 |
| JPS63256336A (ja) * | 1987-04-13 | 1988-10-24 | Yoshiaki Kakino | Ｎｃ機械におけるボ−ルねじの熱変位補正方法 |
| US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| US5169934A (en) * | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
| EP0610179B1 (de) * | 1990-07-20 | 1996-10-16 | Pharmacia AB (reg.number 556131-9608) | Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation |
| SG47099A1 (en) * | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
| JPH07500315A (ja) * | 1991-05-10 | 1995-01-12 | セルトリックス ファーマシューティカルズ，インコーポレイテッド | 骨成長因子の標的送達 |
| US5169627A (en) * | 1991-10-28 | 1992-12-08 | Mount Sinai School Of Medicine Of The City University Of New York | Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity |
| DE59309494D1 (de) * | 1992-05-22 | 1999-05-12 | Ciba Geigy Ag | Hochauflösender I-Linien Photoresist mit höherer Empfindlichkeit |
| JPH06335575A (ja) * | 1993-05-28 | 1994-12-06 | Tokyo Electric Co Ltd | 電気かみそり |
-
1996
- 1996-05-10 WO PCT/JP1996/001241 patent/WO1996035451A1/ja active IP Right Grant
- 1996-05-10 CA CA002220339A patent/CA2220339C/en not_active Expired - Fee Related
- 1996-05-10 EP EP96913722A patent/EP0867190B1/de not_active Expired - Lifetime
- 1996-05-10 AT AT96913722T patent/ATE381948T1/de not_active IP Right Cessation
- 1996-05-10 DE DE69637383T patent/DE69637383T2/de not_active Expired - Lifetime
- 1996-05-10 US US08/981,416 patent/US6103236A/en not_active Expired - Fee Related
- 1996-05-10 JP JP53395196A patent/JP3871713B2/ja not_active Expired - Fee Related
- 1996-05-10 ES ES96913722T patent/ES2299177T3/es not_active Expired - Lifetime
-
2000
- 2000-02-08 US US09/500,243 patent/US6638509B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2220339C (en) | 2009-10-13 |
| EP0867190A1 (de) | 1998-09-30 |
| ATE381948T1 (de) | 2008-01-15 |
| ES2299177T3 (es) | 2008-05-16 |
| WO1996035451A1 (fr) | 1996-11-14 |
| EP0867190A4 (de) | 2002-01-02 |
| JP3871713B2 (ja) | 2007-01-24 |
| US6638509B1 (en) | 2003-10-28 |
| US6103236A (en) | 2000-08-15 |
| DE69637383T2 (de) | 2008-12-11 |
| EP0867190B1 (de) | 2007-12-26 |
| CA2220339A1 (en) | 1996-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69637383D1 (de) | Cytotoxinkonjugate umfassend dipeptide | |
| NO862177D0 (no) | Monoklonale antistoffer til cyklosporinger. | |
| ES2110386T3 (es) | Conjugados de interferon. | |
| NO20025089D0 (no) | Farmasöytiske preparater | |
| EP2270047A3 (de) | Antikörper gegen C5 und deren therapeutischen Verwendungen | |
| ZA903517B (en) | Labeled chemotactic peptides to image focal sites of infection or inflammation | |
| IE861706L (en) | Solubilization of proteins for pharmaceutical compositions¹using polymer conjugation | |
| BR9808491A (pt) | Compostos calcilìticos | |
| ATE369878T1 (de) | Träger-pharmaka-konjugate | |
| NO950651L (no) | Antitranspirasjonsdeodorantpreparat | |
| NZ310847A (en) | High affinity human monoclonal antibodies specific for rsv fusion protein | |
| DE69124435D1 (de) | Reaktive, "hotmelt" elastische Abdichtungszusammensetzung | |
| MY132115A (en) | Novel thrombin inhibitors | |
| WO1999004820A3 (en) | Cytolysis of target cells by superantigen conjugates inducing t-cell activation | |
| AU1519699A (en) | Affinity markers for human serum albumin | |
| AU3258089A (en) | Methods for improving the efficacy of insect toxins | |
| DE69014175D1 (de) | Magnetooptische Wiedergabemethode. | |
| EP0506854A4 (en) | An improved toxin for construction of immunotoxins | |
| ATE346096T1 (de) | G-csf tpo fusionsproteine | |
| AU3300797A (en) | Selenophene anti-tumor agents | |
| DK0815141T3 (da) | Antistof mod et fusionspolypeptid omfattende en histidinandel | |
| ATE276366T1 (de) | Type f botulinum toxin und seine verwendung | |
| ZA967037B (en) | Composition for an artificial track. | |
| FR2697709B1 (fr) | Dispositif d'étanchéité de moteurs électro-acoustiques. | |
| ATE240749T1 (de) | Radioaktivmarkierte annexin-galaktose konjugate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP |